Analyst Ratings For AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG)
Today, Cowen reiterated its Hold rating on AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) with a price target of $13.00.
There are 5 Hold Ratings, 2 Buy Ratings, 1 Sell Ratings, no Strong Buy Ratings on the stock.
The current consensus rating on AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) is Hold with a consensus target price of $17.8750 per share, a potential 108.60% upside.
Some recent analyst ratings include
- 6/24/2019-AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) had its Hold rating reiterated by Cowen with a $13.00 price target
- 6/11/2019-AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) has coverage initiated with a Overweight ➝ Overweight rating and $19.00 price target
- 3/14/2019-AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) had its Hold rating reiterated by Cantor Fitzgerald with a $14.00 price target
- 11/6/2018-AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) gets downgraded to Underweight by JPMorgan Chase & Co. with a price target of $18.00
- On 5/28/2019 Julie Krop, Insider, bought 10,000 with an average share price of $9.91 per share and the total transaction amounting to $99,100.00.
- On 5/9/2019 Elizabeth Scott Bolgiano, Insider, bought 5,000 with an average share price of $10.93 per share and the total transaction amounting to $54,650.00.
- On 5/9/2019 William K Heiden, CEO, bought 10,000 with an average share price of $10.70 per share and the total transaction amounting to $107,000.00.
- On 3/7/2019 Joseph Vittiglio, EVP, sold 1,425 with an average share price of $14.01 per share and the total transaction amounting to $19,964.25.
- On 8/7/2018 William K Heiden, CEO, sold 5,000 with an average share price of $25.00 per share and the total transaction amounting to $125,000.00.
- On 6/4/2018 William K Heiden, CEO, sold 20,000 with an average share price of $25.00 per share and the total transaction amounting to $500,000.00.
- On 3/6/2018 Joseph Vittiglio, EVP, sold 770 with an average share price of $20.80 per share and the total transaction amounting to $16,016.00.
About AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG)
AMAG Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and commercializes therapeutics for maternal and women's health, anemia management, and cancer supportive care in the United States. It markets Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds. Read More…
Recent Trading Activity for AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG)
Shares of AMAG Pharmaceuticals, Inc. closed the previous trading session at 8.58 −0.39 4.35% with 4303768 shares trading hands.